epoetin delta

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Dynepo has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 23/04/2009

Authorisation details

Product details
Agency product number
Active substance
epoetin delta
International non-proprietary name (INN) or common name
epoetin delta
Therapeutic area (MeSH)
  • Kidney Failure, Chronic
  • Anemia
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Shire Pharmaceutical Contracts Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Shire Pharmaceutical Contracts Ltd.
Hampshire International Business Park
Basingstoke, Hampshire RG24 8EP
United Kingdom

Product information

29/02/2008 Dynepo - EMEA/H/C/000372 - II/0020

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antianemic preparations

Therapeutic indication

Dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult patients. It may be used in patients on dialysis and in patients not on dialysis.

Assessment history

How useful was this page?

Add your rating